4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Ophthalmology by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2226 ongoing clinical trials involving Ophthalmology
Of the 2226 trials,809 trials are in Phase III
Furthermore, 575 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Ophthalmology by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Ophthalmology therapy area. The largest number of ongoing clinical trials for indications related to Ophthalmology therapy area is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in drug trials.

Sun Yat-sen University: The leading ongoing clinical trial sponsor for indications related to Ophthalmology therapy area

Sun Yat-sen University is the top clinical trial sponsor for indications related to the Ophthalmology therapy area.

Novartis AG, Santen Pharmaceutical Co Ltd, Zhongshan Ophthalmic Center, and Intratus Inc are a few other notable clinical trials sponsors involved in the Ophthalmology therapy area. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Ophthalmology

Adalimumab (Humira), Aflibercept (Eylea), and Ranibizumab (Lucentis, Patizra) are among the key marketed drugs marketed for the treatment of indications related to the Ophthalmology therapy area.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as an injection for subcutaneous route of administration. Adalimumab is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. It was first approved in 2002 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including AbbVie Inc, Eisai Co Ltd, and Abbott Laboratories.

Aflibercept (Eylea) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. It functions via Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Inhibitor; Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. Eylea is formulated as an iso-osmotic injection solution for intravitreal route of administration. Eylea is indicated for treatment of neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for diabetic macular edema (DME) and Diabetic Retinopathy (DR) in Patients with DME, for the treatment of choroidal neovascularization and macular edema secondary to branch retinal vein occlusion (BRVO), for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), and all stages of non-proliferative diabetic retinopathy (DR), and thereby reduce the risk of blindness. Aflibercept was first approved in 2011 and is marketed globally including the US, the UK, France, and Germany by Regeneron Pharmaceuticals Inc, and Bayer AG.